Endometrial Blood-Clotting Factors and Heostasis in Heavy Menstrual Bleeding
Official title: PAI-1, tPA, TFPI and Endometrial Endothelial Cells in Uterine Hemostasis
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11471295 · Data updated 2026-11-12
A clinician-scientist study will explore how endometrial blood-clotting proteins in menstrual blood relate to heavy menstrual bleeding in people who menstruate.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 15, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $164,376 |
| NIH project number | 7K08HL175118-02 |
| Project ID | NIH-11471295 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who experience heavy menstrual bleeding as well as those without heavy bleeding, willing to provide menstrual blood samples and endometrial tissue.
✕Less likely to help
Individuals who do not have heavy menstrual bleeding and do not participate in tissue sampling may not directly benefit.
What this research studies
This project looks at how factors like tPA, PAI-1, TFPI, and von Willebrand factor are expressed by endometrial cells during a period and whether these patterns differ in people with heavy menstrual bleeding. It will measure these proteins in menstrual blood across the days of a period, compare patterns between those with and without heavy bleeding, and examine endometrial biopsy samples at the single-cell level to see which cells produce these factors. The goal is to understand how endometrial endothelial cells may regulate uterine hemostasis and contribute to heavy bleeding, which could guide new treatments. The work is designed to connect molecular signals with the clinical presentation of heavy menstrual bleeding and its impact on quality of life.
Why it matters
Potential benefit: If successful, the findings could lead to targeted therapies that normalize uterine hemostasis and reduce heavy menstrual bleeding.
How similar studies have gone: Previous research has linked tPA, PAI-1, TFPI, and VWF with menstrual bleeding, but this study combines menstrual blood analysis with single-cell endometrial profiling, making it relatively novel.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Samuelson Bannow, Bethany Tara — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Samuelson Bannow, Bethany Tara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.